The GLP-1 gender gap is a measurable difference in how often men and women with obesity are diagnosed, referred and prescribed GLP-1 receptor agonists such as semaglutide and tirzepatide, and recent research indicates it widened after the FDA approved semaglutide (Wegovy) for chronic weight management in 2021. An analysis of US prescribing data from 2020 to 2024 found that about 3% of eligible women received semaglutide or tirzepatide for obesity, compared with 1.2% of eligible men, according to Medscape Medical News. Men and women develop obesity at similar rates, yet women are far more likely to be prescribed and to use the newer GLP-1-based weight-loss drugs.
The finding matters to the peptide therapy and research peptide industry because GLP-1 agonists are peptides, and every step between a documented diagnosis and a filled prescription — clinical screening, referral, insurance coverage, prescribing and dispensing — determines how much of the addressable patient population actually reaches peptide-based treatment. A persistent sex-based gap in diagnosis and referral implies that demand forecasts built on obesity prevalence alone may overstate near-term prescription volume, while clinics and telehealth operators that systematically screen both sexes may capture patients competitors overlook.
What the new research actually found
A study examining the impact of the FDA’s 2021 approval of semaglutide (Wegovy) for chronic weight management on the GLP-1 usage gap between men and women in the US found similar utilization rates between the sexes before approval. After approval, the authors concluded that the decision “was associated with a sharp increase in GLP-1 utilization…, widening sex-based differences, with female utilization significantly surpassing that of males.” The finding is an association drawn from observational utilization data, not proof that the approval itself caused the divergence; changes in direct-to-consumer marketing, insurance coverage and prescriber behavior occurred over the same period.
The prescribing analysis covering 2020 to 2024 provides the clearest magnitude: roughly 3% of eligible women versus 1.2% of eligible men received semaglutide or tirzepatide for obesity. Both figures are low relative to the eligible population, which suggests that access constraints — not only patient preference — shape who receives treatment.
Key numbers behind the GLP-1 gender gap
| Indicator | Women | Men | Source and period |
|---|---|---|---|
| Eligible patients receiving semaglutide or tirzepatide for obesity | About 3% | 1.2% | US prescribing data analysis, 2020–2024 |
| Effective weight-loss action after referral for weight management | 60.7% | 41.6% | Randomized trial of clinician endorsement and referral |
| Effective weight-loss action after brief advice | 18.3% | 12.1% | Randomized trial of clinician endorsement and referral |
| Referral to community weight-loss programs by general practitioners | Nine times more often than men | Reference group | UK BWeL trial authors |
| Illustrative drug cost cited for Medicare | $245 per prescription | Expert comment citing Medicare payment | |
The randomized trial data are notable because the relative benefit of the intervention did not differ by sex: referral helped men and women by a similar proportion, yet men took effective weight-loss action less often in both arms. That pattern points toward differences in uptake rather than differences in the usefulness of the referral itself.
Why the gap matters for peptide therapy clinics and telehealth
For peptide therapy clinics, medical spas and telemedicine platforms, the diagnosis step is the commercial bottleneck. Hemalkumar Mehta, PhD, of the Johns Hopkins Bloomberg School of Public Health, told Medscape Medical News that height and weight are usually captured at routine visits, so BMI is generally recorded. “What we are missing is the next step, where a high BMI becomes a documented, treatable obesity diagnosis,” he said, adding that the data suggest women are more likely than men to receive that diagnosis. Because diagnosis is the first step toward receiving obesity drugs, documentation practices directly influence who enters the treatment pathway.
The diagnosis gap is not evenly distributed. The study found non-Hispanic Black women and Hispanic women were the most likely to be diagnosed, while non-Hispanic Asian men were the least likely. Clinics that rely on self-referral rather than proactive screening may therefore build patient panels that reflect marketing reach rather than clinical need.
Referral patterns reinforce the same direction. Data from the US and UK show women are more likely than men to be referred to behavioral weight-loss programs, and authors of the UK’s BWeL trial reported that general practitioners referred women nine times more often than men to community weight-loss programs. An early US study found physicians were more likely to encourage women with a BMI of 25 to lose weight than men with the same BMI.
Marketing, stigma and patient preference
Robyn Pashby, PhD, told Medscape Medical News that decades of weight-loss marketing aimed at women mean women may be more likely to recognize weight-loss treatment as something intended for them, pointing to imagery, language, testimonials and messaging that skew toward women. A small qualitative study from Anglia Ruskin University in Cambridge, UK, supports that view: participants described dieting as a largely female-focused activity, and most men said they would feel self-conscious and uncomfortable engaging in dieting conversations. The same study found men often associated dieting with being denied food they enjoy.
A study on shared decision-making in obesity and type 2 diabetes found men tend to express less body dissatisfaction, be less interested in weight loss and be less likely to seek obesity treatment than women. These are reported findings from specific studies, not universal statements about individual patients, and they do not establish that any given man declined care because of stigma.
Research and market context for peptide-based obesity drugs
Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors; their approved products, indications, dosing and labeling differ, and treatment decisions should rest on the relevant product labeling and professional evaluation. Both are prescription medicines, and neither is a research peptide. Research-use peptides are supplied for laboratory work and are not authorized for human administration; a research-use designation does not establish sterility, safety or suitability for patients.
For suppliers and buyers across the peptide supply chain, the practical read-across is about demand composition rather than molecule-level science. If a meaningful share of eligible men never receive a documented diagnosis, then prescription volumes observed today understate prevalence-based demand but may overstate how quickly that demand converts into filled prescriptions. Companies tracking GLP-1 peptide API demand, finished injectable capacity and injection pen or dual-chamber cartridge programs should treat diagnosis and referral rates as leading indicators, not just obesity prevalence. 多肽供应链资源网 as a provider in the industry domain tracks this kind of upstream and downstream supply information for peptide businesses.
Coverage remains a separate constraint. Angela Fitch, MD, told Medscape Medical News that a population-health focus on metabolic health and obesity treatment is needed but cannot be achieved until coverage exists, and she argued for standard benefit coverage. She also cited data indicating that treating obesity saves the healthcare system money, especially when patients have comorbidities, and gave an illustrative example in which a drug costing $245 — comparable to what Medicare pays — would still produce savings. That figure is an expert illustration, not a general pricing statement.
What comes next
Mehta recommended closing the diagnosis gap first: recording men’s obesity diagnosis in the electronic health record the same way it is recorded for women, then starting the conversation with men as routinely as with women. Pashby called for normalizing the conversation and positioning obesity as a chronic, treatable medical condition rather than waiting for patients to raise concerns. She noted that some clinicians worry about handling the discussion poorly, others are too busy or overwhelmed, and still others do not accept that obesity is a medical condition.
Both experts were cautious about reframing GLP-1 treatment around testosterone or masculinity. A conference presentation reported that testosterone levels rose in men on GLP-1s, prompting some suggestions that men might be motivated by that framing, but Mehta said he would be cautious and described it as a short-term solution even if it worked. Pashby warned against replacing one set of body expectations with another.
For industry readers, the next observable signals are documentation rates for obesity diagnoses in men, referral volumes by sex, and coverage decisions for obesity treatment. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. Additional supply-side context is available through peptidescm.
Frequently asked questions
What is the GLP-1 gender gap?
It is the measured difference between men and women in obesity diagnosis, referral and GLP-1 prescription. US prescribing data from 2020 to 2024 showed about 3% of eligible women received semaglutide or tirzepatide for obesity versus 1.2% of eligible men.
Did the 2021 Wegovy approval cause the gap?
The study found similar utilization between sexes before approval and a sharp increase afterward that widened sex-based differences. The authors described this as an association, and observational data cannot by themselves establish causation.
Are GLP-1 drugs peptides?
Yes. Semaglutide and tirzepatide are peptide-based prescription medicines with distinct receptor activity and labeling. They are not research peptides and should not be confused with research-use-only materials.
What can clinics do about the gap?
Experts quoted in the reporting recommend documenting obesity diagnoses for men as consistently as for women, initiating weight-related conversations routinely, and treating obesity as a chronic medical condition. Any prescribing decision requires medical supervision.
Comments